The new decision, made by the Ministry of Health and Human Services, aims to have the Emergent BioSolutions plant in Baltimore focus entirely on Johnson & Johnson’s Covid-19 vaccine production. It also avoids the same manufacturing problems as happened with the 15 million doses of Johnson & Johnson vaccine.
Earlier, on March 31, the New York Times reported that 15 million doses of Covid-19 vaccine of Johnson & Johnson pharmaceutical company were damaged during production at the Emergent BioSolutions factory in Baltimore.
Johnson & Johnson later confirmed there was a batch of substandard drugs. However, this batch of pharmaceutical substance has not been put into the final stages of the production line.
Pharmaceutical company Johnson & Johnson also decided to add experts in production, professional operations and quality to Emergent factory to supervise, direct and support all production stages of Covid-19 vaccine.